Articles tagged with Drug Discovery
Research reveals that tau protein undergoes stepwise chemical modifications over time, correlating with dementia stage in Alzheimer's disease. The discovery suggests that multiple drugs may be necessary to target tau effectively, with early intervention requiring different therapeutics compared to late-stage treatment.
Researchers from Osaka University have developed a technique to visualize small-molecule drugs in cells using gold nanoparticles and surface-enhanced Raman scattering (SERS) microscopy. This approach allows for real-time observation of the dynamics of small molecules inside target cells, providing valuable insights for drug discovery.
The University of Luxembourg is pioneering the use of machine learning to identify potent drug candidates and accelerate pharmaceutical development. By combining quantum mechanics and large molecular datasets, researchers hope to overcome challenges in chemical discovery and create novel compounds with tailored properties.
A new machine learning model has been developed to help characterize compounds in the development of new drugs. The model uses tandem mass spectrometry and is based on a small amount of positive and negative training data, making it useful for automating characterization of compounds by chemists.
Insilico Medicine will showcase its latest AI advancements in drug discovery and productive longevity at the Leveraging Intelligent Tech for Drug Development Forum. The company's work on AI-generated molecular structures, synthetic biological data, and clinical trial prediction has garnered significant attention and funding.
The Mark Foundation has launched a new funding program for novel cancer therapeutics. Two projects have been selected, focusing on Ewing sarcoma and leukemias, targeting USP7 and CBP/p300 enzymes with highly selective inhibitors.
Researchers have created ultrapotent compounds to treat Clostridioides difficile (C. diff), a leading cause of healthcare-associated infections in the US. The compounds show significant advantages over current antibiotics, including minimum inhibitory concentration values as low as 0.003 μg/mL and improved prevention of recurrence.
South Rampart Pharma, a New Orleans life science company, has been awarded a $1.9 million NIH STTR grant to develop a new class of non-opioid medicines for pain relief and fever reduction. The company aims to create a safer treatment option for acute and chronic pain, which affects hundreds of millions of people worldwide.
Researchers at Gruthan Bioscience aim to develop a new class of cholesterol-lowering drugs for patients with familial hypercholesterolemia, a rare form of high cholesterol. The startup plans to use its novel cell platform to identify and test promising compounds.
Researchers at UNC-Chapel Hill and Stanford solve the high-resolution structure of psychedelic compounds bound to the 5-HT2A serotonin receptor, revealing key insights into their therapeutic potential. The discovery sets the stage for the exploration of more precise compounds with strong therapeutic effects.
Researchers discovered that hollow multishelled structures can realize sequential drug release through unique temporal-spatial order property. This property enables burst, sustained, and stimulus-responsive release stages, providing a long sterility period in bacteria-rich environments.
Researchers studied the binding of general anesthetics and benzodiazepines to the GABAA receptor in the brain. They found that both types of drugs can bind to multiple sites on the receptor, with differences between them. This discovery could lead to the development of new, more selective anesthetics with fewer side effects.
Austrian researchers identified drug-like compounds that could block a key coronavirus protein called PLpro, found in all coronaviruses. These compounds previously developed to fight SARS showed promise in halting the growth of COVID-19 virus (SARS-CoV-2) in laboratory testing.
Researchers at Waseda University have created a novel method to produce alicyclic compounds from commercially available arenes, promising to accelerate drug discovery research. The new method uses a palladium catalyst and malonates as reactants, producing highly functionalized molecules with diverse properties.
Researchers at UC Riverside developed a drug discovery pipeline to identify effective drugs for treating COVID-19. The team used a powerful machine-learning approach to screen millions of chemicals and identified hundreds of promising candidates, including some that are already FDA-approved.
Rice University scientists have won a $1.9 million NIH grant to explore the use of CRISPR-Cas genome editing in natural fungi to discover new drugs that stay ahead of disease resistance. By understanding how fungi synthesize useful compounds, they aim to create novel drug development toolkits.
A new process developed by SFU chemist Robert Britton and his team allows for the creation of new nucleoside analogues in a fraction of the time previously required. This breakthrough has significant implications for treating viral infections and cancer.
Researchers have developed a catalytic system that directly installs the trifluoromethyl group onto arenes using trifluoroacetic acid. The new reaction offers a milder alternative to existing strategies and has been successfully applied to a diverse array of arenes and heteroarenes.
A new technology dubbed MorphEUS enables rapid screening of drug candidates against Mycobcterium tuberculosis (M. tb), the bacterium that causes TB. It uses high throughput imaging and machine learning to uncover patterns in how antibacterials kill, improving the efficiency and effectiveness of treatment development.
A study supported by the Alzheimer's Drug Discovery Foundation found that rotigotine, a dopamine-acting drug, improved frontal lobe executive function and daily activities in patients with mild-to-moderate Alzheimer's disease. The treatment also enhanced dopaminergic pathways reaching this section of the brain.
Researchers at Istituto Italiano di Tecnologia have discovered a novel chemical compound that shows promise in treating core symptoms of brain disorders such as Down syndrome and autism. The new compound selectively blocks the transporter NKCC1, which is dysregulated in these conditions.
Eugenia Trushina, Ph.D., Mayo Clinic Rochester researcher, receives $600,000 to develop new drug candidates restoring mitochondrial function in treating Alzheimer's. The ADDF-Harrington partnership aims to accelerate discovery into clinical studies for a potential cure.
TARA's in vitro human cardiac models replicate drug responses similar to those observed in humans, supporting their use as a robust platform for new medicines evaluation. The models' ability to reproduce diverse mechanisms of action showcases their applicability for cardiac drug discovery and development.
Researchers developed a machine learning algorithm to predict six major clinical forms of drug-induced cardiac toxicity from gene expression data. The model demonstrated generalizability and was validated on an independent dataset, with potential applications in enhancing pharmaceutical industry safety evaluation.
Scientists have discovered a new killing mechanism in teixobactin, a potent natural antibiotic that can kill superbugs. The research provides fundamental insights into how teixobactins work and could lead to the development of new drugs.
Research at Kobe University reveals that metformin causes blood sugar to be excreted in the stool, promoting its removal from the intestine. This discovery contributes to understanding the mechanism of metformin's biological effects and may lead to the development of new drugs for diabetes.
KinaRx LLC, a Purdue University-affiliated startup, has received a $2 million SBIR grant to develop novel kinase inhibitors for treating relapse in acute myeloid leukemia (AML) and other diseases. The company's platform aims to rapidly create complex drug molecules using bioinformatics and multi-component compound synthesis.
A special collection in SLAS Discovery highlights new screening tools and assays for ion channel drug discovery. The articles cover various techniques such as optical and automated patch clamp electrophysiology to identify new chemical matter for medically relevant membrane protein targets.
The Chemical Checker tool uses a similarity principle to analyze over 1M compounds and identify potential treatments for diseases. It has been used to reposition approved drugs for Alzheimer's disease and identify substitutes for expensive biologics.
A team of computational scientists, medicinal chemists, biochemists, and virologists have coalesced to rapidly identify drug-like molecules that inhibit SARS-CoV-19 replication. They are leveraging powerful supercomputers to screen millions of small molecules against all the major non-structural proteins of SARS-CoV-19.
Researchers are developing new metal catalysts for drug discovery, potentially offering lower therapeutic dosages and fewer side effects. The project aims to create synthetic forms of biological macromolecules that detoxify aldehydes, addressing biochemical imbalance and disease development.
A USC-led team of scientists has discovered the precise shape of the melanocortin 4 receptor, a key player in human metabolism. The findings could lead to more effective therapies for obesity and other metabolic diseases, which affect millions worldwide.
Researchers unveil the structure of a key protein in human metabolism, which could lead to better obesity treatments. The study found that calcium ions play a crucial role in the protein's function, opening new paths for developing targeted pharmaceuticals.
Multispecific drugs have the potential to target 85% of currently thought-of-as-undruggable proteins. By inducing proximity between targets and natural enzymes or cells, they can harness biology's power to go beyond conventional drugs.
An international team of researchers has identified six potential COVID-19 treatment candidates after testing over 10,000 compounds. The targeted therapeutics were found to be effective in inhibiting the main protease enzyme of the virus.
Gero's AI platform identifies 9 potential COVID-19 treatments among existing drugs, including Niclosamide and Nitazoxanide. The list enables urgent clinical trials to begin in weeks.
Experts debate nationalizing the pharmaceutical sector to improve public health priorities, address extortionate pricing, and ensure patient access to new advanced drugs. Mariana Mazzucato and Henry Lishi Li propose a government-provided quality-assured medicine option that co-exists with private sector products.
The discovery of CRISPR-Cas9 systems has revolutionized pharmaceutical research by allowing for industrial-scale gene editing and functional genomic screening. This enables the identification of new biological targets for precision medicines and the exploration of mechanisms of drug resistance and sensitivity ahead of clinical trials.
Researchers at Emory University have developed a new approach to organic synthesis that can efficiently transform simple molecules into complex ones with 3D structures. This method opens up whole new chemical space for potential drug targets, enabling the creation of more direct and efficient pathways for pharmaceutical research.
A novel injectable drug, NOV004, is being developed by Novosteo Inc. to heal broken bones faster and strengthen weak bones. The treatment concentrates at the fracture site while reducing exposure to the rest of the body, potentially reducing mortality rates among older adults.
A new minimally invasive treatment has shown significant improvement in symptoms and quality of life for patients with thyroid eye disease. The drug, teprotumumab, blocks inflammatory autoimmune pathophysiology and has the potential to alter the course of the disease.
Calibr's novel cell therapy leverages a patient's own immune cells, directing them to engage cancer targets with a control switch. Clinical trials will test the approach in patients with relapsed/refractory B-cell malignancies.
Researchers are developing long-acting formulations for malaria and TB prevention, as well as a single-injection cure for hepatitis C. The project aims to improve patient adherence and reduce disease transmission in low- and middle-income countries.
Researchers mapped protein-drug interactions in rat organs and blood, revealing potential drug targets. The study represents a significant advancement for translational research, allowing direct monitoring of biological changes in an organ.
Researchers at the University of Dundee are working on a new effort to tackle tuberculosis, identifying new treatment options for the disease. With a $3 million grant from the Bill & Melinda Gates Foundation, they aim to improve drug discovery and develop new candidate drugs to treat TB.
The National Cancer Institute's Plated Compound Sets provide a convenient and cost-effective way to screen compounds manually. However, some collections contain pan assay interfering and nonspecific compounds that can generate false hits.
Lemon, a new framework, enables faster extraction of biological information from large datasets, enhancing drug development. The software can process PDB data in minutes, reducing time from hours to seconds.
TARA Biosystems' human heart-on-a-chip technology shows promise in predicting preclinical systolic and diastolic in vivo observations for novel cardiac drug MYK-491. The platform uses human induced pluripotent stem cells to create physiologically relevant cardiac tissues.
Researchers developed a free online app, eNTRyway, to speed up the discovery of new antibiotics for Gram-negative bacteria. The tool quickly evaluates potential drug compounds and can convert existing drugs into potent killers of Gram-negative pathogens.
Researchers have identified a new enzyme that inhibits the LRRK2 pathway, which is responsible for most genetic cases of Parkinson's disease. The discovery provides hope for developing new treatments and suggests that the enzyme could benefit all individuals, regardless of whether they have Parkinson's or not.
Researchers at the University of Dundee have discovered an enzyme that could prevent Group A Streptococcus infections by inhibiting a carbohydrate coating on the bacterium's surface. The discovery offers new opportunities for developing antimicrobial drugs with minimal off-target effects.
Chemists at Ohio State University have discovered a new way to synthesize the most common molecule arrangement in medicine, which could make it easier and more efficient for drug makers to produce medicines. This breakthrough could lead to a reduction in waste and an improvement in the production process.
A new drug discovery platform created by Purdue University scientists has the potential to predict the effectiveness of psychoactive drugs in treating mental health illnesses. The platform analyzes compound interactions with proteins and identifies signature patterns for potential therapeutic uses.
The company has proposed a new family of prior distributions: TRIP, which improves Fréchet Inception Distance for GANs and Evidence Lower Bound for VAEs. The model was experimentally validated in cells and animals, demonstrating its potential for accelerating drug discovery.
George Mason University researchers have discovered the exact location where two proteins responsible for hiding cancer cells from the immune system bind. The protein painting technology enables rapid performance testing of drugs, producing results in several days instead of years.
The National Institute on Aging has awarded a grant to establish the Open-AD Drug Discovery Center, which aims to accelerate the development of new drugs for Alzheimer's disease. The center will develop research platforms and openly distribute tools to test the efficacy of Alzheimer's therapies.
The IU-led center will focus on proteins related to the brain's immune system that may contribute to Alzheimer's disease. The goal is to develop high-quality research tools and new technologies needed to broaden the number of targets being investigated for effective medicines.
Researchers are using cloning to recreate esophageal cancer development, identifying potential targets for therapies before the disease becomes fatal. The goal is to develop effective drugs in a fraction of the time it takes Big Pharma.
Researchers developed a method to categorize drugs based on cellular responses, predicting potential clinical effects and reducing side effects. The approach was validated using opioid analgesics, with potential applications in safer opioids and cannabis product testing.
Researchers have developed an AI-powered drug discovery tool that validates novel drug candidates in just 46 days, significantly reducing the traditional 2-3 year timeline. The foundation aims to motivate researchers to harness AI's potential in longevity research and encourage larger developers to adopt AI-powered programs.